Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Hair Loss Treatment in Transgender Patients: Gender-Affirming Approaches and Algorithms
Description
The talk explains gender-affirming hair loss management in transgender patients, emphasizing that hormones strongly influence scalp and body hair: androgens promote miniaturization and androgenetic alopecia, while estrogens support hair density and prolong anagen. In trans men on testosterone, 32–63% may develop androgenetic alopecia, with risk increasing by age, family history, and duration of therapy. First-line treatment is topical minoxidil 5%, with oral minoxidil as an option, but finasteride should generally be delayed for 1–2 years to avoid interfering with masculinization; it can also reduce libido and may cause return of menstruation, so pregnancy risk must be considered. Alternatives include oral minoxidil, topical finasteride, dutasteride, and low-level laser therapy, while spironolactone should be avoided because it lowers testosterone and counteracts masculinization. In trans women, estrogen-based therapy supports feminization and may improve scalp hair, but does not adequately remove facial hair, so additional treatments are needed. Options include spironolactone, topical minoxidil, finasteride, oral minoxidil, dutasteride, topical combinations, PRP, and low-level laser therapy. Facial hair removal is best treated with electrolysis, with laser as another option, and topical eflornithine can be added. Surgical approaches such as hairline feminization in trans women and beard restoration in trans men may also be considered. The main message is that care should be individualized, coordinated with endocrinology, and attentive to psychological impact.
View moreConclusions
- Hair loss management in transgender patients should be individualized to preserve gender-affirming goals while addressing distressing alopecia.
- In trans men, testosterone commonly increases the risk of androgenetic alopecia, especially with genetic predisposition and longer exposure to therapy.
- First-line treatment for trans men is topical minoxidil, with finasteride or other anti-androgenic treatments introduced cautiously and usually after waiting for masculinization to stabilize.
- Spironolactone should generally be avoided in trans men because it lowers testosterone and can counteract masculinization.
- In trans women, feminizing hormone therapy can reduce body hair and may improve scalp hair, but it does not reliably eliminate facial hair.
- For trans women, management of hair loss often combines hormone therapy with hair-directed treatments such as spironolactone, minoxidil, finasteride, and adjunctive procedures.
- Electrolysis is presented as the gold standard for permanent facial hair removal in trans women.
- Surgical and procedural options, including hairline feminization, hair transplantation, and beard restoration, can be useful when medical therapy is insufficient.
- The psychological and psychosocial impact of hair loss is substantial and should be explicitly addressed in care planning.
- Optimal outcomes require coordination with endocrinologists and an affirming multidisciplinary approach.
- Gao Y, Maurer T, Paradi Mirmirani P. Understanding and Addressing Hair Disorders in Transgender Individuals. Am J Clin Dermatol. 2018;19(4):517-527.#10.1007/s40257-018-0343-z
- Gao JL, Streed CG Jr, Thompson J, Dommasch ED, Peebles JK. Androgenetic alopecia in transgender and gender diverse populations: A review of therapeutics. J Am Acad Dermatol. 2023 Oct;89(4):774-783.#10.1016/j.jaad.2021.08.067
- Tang GT, Zwickl S, Sinclair R, Zajac JD, Cheung AS. Clinical and Experimental Dermatology review on gender-affirming hormone therapy and hair growth (2023).